Yervoy (Prostate Cancer) – Forecast and Market Analysis to 2022

GlobalData has released its new PharmaPoint Drug Evaluation report, “Yervoy (Prostate Cancer) – Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease. BMS’ Yervoy is a therapeutic monoclonal antibody that binds to CTLA-4 and blocks its interaction with the ligands CD80/CD86 that are expressed on antigen-presenting cells. It is currently marketed for advanced melanoma. This enhances T-cell activation and proliferation, which may induce a T-cell-mediated, anti-tumor immune response. Yervoy is currently being developed as a first-line monotherapy or a second-line combination therapy with radiotherapy for mCRPC. It is administered intravenously once every four weeks for the induction cycle, and once every 12 weeks in the maintenance phase of treatment.

Scope

Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Yervoy including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Yervoy for the top nine countries from 2012 to 2022.

Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Yervoy performance

Obtain sales forecast for Yervoy from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)

Table of Contents

1Table of Contents1

1.1List of Tables3

1.2List of Figures3

2Executive Summary4

2.1Sales for Yervoy in Prostate Cancer by Region4

2.2What do the Physicians Think?5

3Introduction7

3.1Catalyst7

3.2Related Reports7

3.3Upcoming Related Reports9

4Disease Overview10

4.1Etiology and Pathophysiology10

4.1.1Etiology10

4.1.2Pathophysiology10

4.1.3Prognosis11

4.1.4Quality of Life12

4.2Symptoms12

5Disease Management13

5.1Diagnosis and Referral Overview13

5.2Treatment Overview14

5.2.1Conservative Management Strategies18

5.2.2Localized Treatments19

5.2.3Hormone Therapy20

5.2.4Drug Therapies21

6Competitive Assessment22

6.1Overview22

6.2Strategic Competitor Assessment23

7Opportunity and Unmet Need26

7.1Overview26

7.2Efficacy at Prolonging Overall Survival27

7.3Safety27

7.4Mitigation of Symptoms28

7.5Cost28

7.6Convenient Routes of Administration28

7.7Accurate Diagnostic Tests and Surveillance Tools28

7.8Unmet Needs Gap Analysis29

7.9Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer30

8Pipeline Assessment31

8.1Overview31

8.2Promising Drugs in Clinical Development32

9Yervoy (ipilimumab)34

9.1Overview34

9.2Efficacy35

9.3Safety36

9.4Dosing and Formulation36

9.5Potential Clinical Positioning37

9.6Potential Commercial Positioning37

9.7Pricing and Reimbursement38

9.8SWOT Analysis38

9.9Forecast40

10Appendix41

10.1Bibliography41

10.2Abbreviations44

10.3Methodology46

10.4Forecasting Methodology46

10.4.1Number of Prostate Cancer Patients Currently Seeking Treatment46

10.4.2Percent Drug-treated Patients46

10.4.3Percent Hormone Therapy-Treated Patients47

10.4.4General Pricing Assumptions47

10.4.5Individual Drug Assumptions48

10.4.6Generic Erosion49

10.4.7Pricing of Pipeline Agents49

10.5Physicians and Specialists Included in This Study49

10.6Survey of Prescribing Physicians50

10.7About the Authors51

10.7.1Authors51

10.7.2Global Head of Healthcare51

10.8About GlobalData52

10.9Contact Us52

10.10Disclaimer52

List of Tables

Table 1: Yervoy: Key Metrics in Prostate Cancer Markets4

Table 2: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets11

Table 3: Global Variations in Recommendations on Routine PSA Screening13

Table 4: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 201215

Table 5: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 201217

Table 6: Leading Treatments for Prostate Cancer, 201225

Table 7: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer – Current Level of Attainment26

Table 8: Overall Unmet Needs, CRPC – Current Level of Attainment27

Table 9: Clinical Unmet Needs – Gap Analysis, 201229

Table 10: Prostate Cancer – Phase III Pipeline, 201232

Table 11: Comparison of Therapeutic Classes in Development for Prostate Cancer, 201232

Table 12: Product Profile – Yervoy34

Table 13: Yervoy SWOT Analysis, 201239

Table 14: Global Sales Forecasts ($m) for Yervoy, 2012-202240

Table 15: Physicians Surveyed, By Country50

List of Figures

Figure 1: Sales for Yervoy by Region, 20225

Figure 2: General Treatment Algorithm for Prostate Cancer, 201216

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-202233

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports